Celularity, Inc. (NASDAQ:CELU) Sees Large Growth in Short Interest

Celularity, Inc. (NASDAQ:CELU) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 483,285 shares, an increase of 26.6% from the December 15th total of 381,786 shares. Approximately 2.1% of the shares of the company are sold short. Based on an average daily volume of 108,359 shares, the days-to-cover ratio is presently 4.5 days. Based on an average daily volume of 108,359 shares, the days-to-cover ratio is presently 4.5 days. Approximately 2.1% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celularity in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.00.

Celularity Stock Performance

Shares of NASDAQ CELU traded up $0.02 during midday trading on Friday, hitting $1.31. 26,469 shares of the stock traded hands, compared to its average volume of 66,642. Celularity has a one year low of $1.00 and a one year high of $4.35. The company has a market cap of $37.31 million, a PE ratio of -0.39 and a beta of 0.80. The business has a 50 day moving average price of $1.55 and a two-hundred day moving average price of $2.21.

Celularity (NASDAQ:CELU) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.62. The company had revenue of $5.28 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CELU. Vanguard Group Inc. lifted its position in Celularity by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after acquiring an additional 176,518 shares in the last quarter. Yorkville Advisors Global LP bought a new position in shares of Celularity in the third quarter worth approximately $207,000. Valmark Advisers Inc. bought a new stake in Celularity during the second quarter valued at about $98,000. HB Wealth Management LLC purchased a new position in Celularity in the 3rd quarter worth approximately $84,000. Finally, Bank of America Corp DE grew its stake in Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after acquiring an additional 35,023 shares in the last quarter. 19.02% of the stock is currently owned by institutional investors.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.